Active, not recruitingPhase 2NCT05032040
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Studying Clear cell adenocarcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xencor, Inc.
- Principal Investigator
- Jolene ShorrXencor, Inc.
- Intervention
- vudalimab(biological)
- Enrollment
- 170 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (17)
- Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona, United States
- UCSD Moores Cancer Center, La Jolla, California, United States
- Valkyrie Clinical Trials, Los Angeles, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- Kaiser Permanente Medical Group, Riverside, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Rocky Mountain Cancer Centers, Aurora, Colorado, United States
- Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Comprehensive Cancer Centers of Nevada-Southern Hills, Las Vegas, Nevada, United States
- NYU Langone Health, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
- +2 more locations on ClinicalTrials.gov
Collaborators
ICON plc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05032040 on ClinicalTrials.govOther trials for Clear cell adenocarcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100M.D. Anderson Cancer Center
- RECRUITINGNCT06279104A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryTongji Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerElizabeth K. Lee MD
- ACTIVE NOT RECRUITINGPHASE1NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc.
- RECRUITINGPHASE1, PHASE2NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT03348631Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerNational Cancer Institute (NCI)